Table 1.
Top canonical pathways | |||
Name | P value | Overlap | |
1 | 3-phosphoinositide degradation | 1.12E-03 | 6.2% 9/146 |
2 | Primary immunodeficiency signaling | 3.18E-03 | 11.4% 4/35 |
3 | D-myo-inositol-5-phosphate metabolism | 4.49E-03 | 5.4% 8/147 |
4 | Superpathway of inositol phosphate compounds | 6.11E-03 | 4.8% 9/188 |
5 | 3-Phosphoinositide biosynthesis | 6.38E-03 | 5.1% 8/156 |
Top upstream regulators | |||
Name | P value | Predicted activation | |
1 | IL3 | 3.85E-07 | |
2 | IL21 | 1.38E-05 | Inhibited |
3 | IL15RA | 1.69E-05 | |
4 | IFNA2 | 4.21E-05 | Inhibited |
5 | TLN1 | 5.55E-05 | |
Causal network | |||
Name | P value | Predicted activation | |
1 | MAP3K13 | 4.93E-07 | Inhibited |
2 | Interferon beta-1a | 5.66E-07 | |
3 | TLR7 | 6.02E-07 | Inhibited |
4 | KAT7 | 7.48E-07 | Activated |
5 | Androgen-AR | 2.10E-06 | Inhibited |
Top diseases and bio functions | |||
Diseases and disorders | |||
Name | P value range | Number of molecules | |
1 | Cancer | 9.16E-03–5.36E-06 | 287 |
2 | Hematological disease | 8.80E-03–5.36E-06 | 106 |
3 | Immunological disease | 8.80E-03–5.36E-06 | 131 |
4 | Organismal injury and abnormalities | 9.27E-03–5.36E-06 | 291 |
5 | Inflammatory response | 6.92E-03–2.02E-05 | 46 |
Molecular and cellular functions | |||
Name | P value range | Number of molecules | |
1 | Cellular development | 9.27E-03–5.57E-07 | 111 |
2 | Cellular growth and proliferation | 9.27E-03–5.57E-07 | 113 |
3 | Cell death and survival | 9.18E-03–4.80E-06 | 117 |
4 | Cell cycle | 9.18E-03–4.80E-06 | 63 |
5 | Cell-to-cell signaling and interaction | 9.27E-03–2.02E-05 | 59 |
Physiological system development and function | |||
Name | P value range | Number of molecules | |
1 | Hematological system development and function | 9.27E-03–4.13E-08 | 84 |
2 | Hematopoiesis | 9.27E-03–4.13E-08 | 54 |
3 | Tissue development | 9.27E-03–5.57E-07 | 75 |
4 | Embryonic development | 9.27E-03–6.04E-06 | 57 |
5 | Lymphoid tissue structure and development | 9.27E-03–6.04E-06 | 60 |